Get the Stockscreener App
5.77
0.35%
0.02
After Hours:
5.57
-0.20
-3.47%
Evaxion A S Adr stock is traded at $5.77, with a volume of 156.05K.
It is up +0.35% in the last 24 hours and up +6.26% over the past month.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
See More
Previous Close:
$5.75
Open:
$5.89
24h Volume:
156.05K
Relative Volume:
0.10
Market Cap:
$36.45M
Revenue:
-
Net Income/Loss:
$-11.46M
P/E Ratio:
-0.4121
EPS:
-14
Net Cash Flow:
$-24.56M
1W Performance:
-5.87%
1M Performance:
+6.26%
6M Performance:
+267.52%
1Y Performance:
-55.44%
1-Day Range:
$5.5101
$5.98
1-Week Range:
$5.5101
$6.82
52-Week Range:
$1.20
$13.80
Evaxion A S Adr Stock (EVAX) Company Profile
Compare EVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
5.77 | 45.56M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-12-24 | Initiated | H.C. Wainwright | Buy |
Evaxion A S Adr Stock (EVAX) Latest News
Evaxion raises $7.2 million, extending cash runway to second half of 2027 - GlobeNewswire Inc.
European ADRs Barely Budge While Gainers And Losers Trade Places - Finimize
Evaxion A/S (NASDAQ:EVAX) Given Buy Rating at HC Wainwright - Defense World
European ADRs Edge Higher As Healthcare Leads Gains - Finimize
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Sees Large Growth in Short Interest - Defense World
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough - ts2.tech
Biotech Stocks Lead European ADRs Higher On Wall Street - Finimize
European Biotech Stocks Outperformed As Broader Market Dipped - Finimize
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Evaxion Biotech price target raised to $16 from $14 at H.C. Wainwright - MSN
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Evaxion Biotech out-licensed vaccine candidate EVX-B3 to MSDMerck - TipRanks
Evaxion A/S (NASDAQ:EVAX) Trading Down 0.7% – Should You Sell? - Defense World
Evaxion Biotech A/S Adr Earnings Call: Strategic Growth Amid Challenges - TipRanks
Evaxion Biotech Reports Q2 2025 Financial Results - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for Week - MSN
XTX Topco Ltd Makes New Investment in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) - Defense World
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 148.8% - Defense World
Evaxion Boosts Equity through Debt Conversion, Improves Financial Flexibility - AInvest
Healthcare Stocks to Watch: Evaxion Biotech, CVRx, and Rockwell Medical Receive Bullish Sentiments - AInvest
Biotech Contrarians: Seizing Value in Europe's ADRs Amid Sectoral Slump - AInvest
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
European ADRs Dip With Some Stocks Rising Above The Crowd - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
Evaxion A/S: Shareholders Board Members Managers and Company Profile | US29970R3030 - MarketScreener
European Equities See Growth In US Trade - Finimize
Analysts’ Top Healthcare Picks: Encompass Health (EHC), Evaxion Biotech (EVAX) - The Globe and Mail
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):